Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
S-1 monotherapy in patients with advanced biliary tract cancer
Oncology (Karger), 06/30/09
Sasaki T et al. - In a trial to evaluate the efficacy and safety of single-agent S-1 in pts with advanced biliary tract cancer, it was reported that S-1 monotherapy is a feasible and moderately efficacious treatment for advanced biliary tract cancer, as a first- or second-line chemotherapy regimen.
Methods- S-1 was administered orally at a dose of 80 mg/m2 for 28 days, followed by 14 days of rest (1 cycle).
- Treatment was repeated until disease progression, unacceptable toxicity, or pt refusal.
- 45 pts were enrolled; among these, 29 pts received S-1 as first-line chemotherapy and 16 pts received S-1 as second-line chemotherapy.
- Response rates for first- and second-line chemotherapy were 17.2 and 18.8%, respectively.
- Median times to progression for first- and second-line chemotherapy groups were 4.2 and 5.5 mos, respectively.
- Median overall survival and 1-yr survival rate for each group were 8.7 and 8.0 mos and 42.2 and 38.2%, respectively.
- Only the first-line chemotherapy group experienced grade 3/4 toxicities, including leukopenia (6.9%), neutropenia (10.3%), anemia (6.9%), thrombocytopenia (10.3%) and total bilirubin elevation (3.4%).
Related Articles
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer
Annals of Oncology, 10/19/09
Relevance Score: 45%
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study : The Lancet Oncology
The Lancet Oncology - Online First, 10/09/09
Relevance Score: 44%
Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)
Annals of Oncology, 11/06/09
Relevance Score: 43%
A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity
European Journal of Surgical Oncology, 10/28/09
Relevance Score: 40%
Completely Displaced S-1/S-2 Growth Plate Fracture in an Adolescent: Case Report and Review of Literature
Journal of Orthopaedic Trauma, 10/28/09
Relevance Score: 40%
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Loss of imprinting of the insulin-like growth factor II (IGF2) gene in esophageal normal and adenocarcinoma tissues
Carcinogenesis, 12/15/09
Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44
Carcinogenesis, 12/15/09
Toxicity against gastric cancer cells by combined treatment with 5-fluorouracil and mitomycin c: Implication in oxidative stress
Cancer Chemotherapy and Pharmacology, 12/15/09
Today in Hepatobiliary/Pancreas...keeping you current
Receive free subspecialty "5-minute updates" via email
An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3' untranslated region confers risk for hepatocellular carcinoma
Carcinogenesis, 12/15/09
Are patients of low socioeconomic status receiving suboptimal management for pancreatic adenocarcinoma
Cancer, 12/15/09
MicroRNA in pancreatic cancer: Pathological, diagnostic and therapeutic implications
Cancer Letters, 12/15/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme
Journal of Neuro-Oncology, 12/15/09
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines
Cancer Chemotherapy and Pharmacology, 12/15/09
Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol
Cancer, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


